Skip to main
ORGO
ORGO logo

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings Inc. has demonstrated a solid performance amidst challenging market dynamics, positioning itself favorably as the reimbursement landscape evolves within the advanced wound care sector. The company benefits from an extensive portfolio of regenerative medicine products, with significant growth potential indicated by a projected operating profit increase and a final rate adjustment for reimbursement slated for CY2026. With shares currently trading at a discount compared to peers and an under-penetrated market opportunity, the outlook for further gains and market share expansion remains strong for Organogenesis Holdings.

Bears say

Organogenesis Holdings Inc. is facing significant challenges that warrant a negative outlook, particularly concerning its revenue growth and operational expenses. The company has been burdened by rising research and development costs without anticipated improvements in financial performance, leading to concerns over the growth of its key product PuraPly and the impact of Medicare Part B pricing on amniotic products. Additionally, the potential for competitive pressures and regulatory hurdles may hinder the company's ability to capture market share, compounded by expectations of reduced sales force effectiveness and higher operational costs associated with ongoing programs, such as the ReNu initiative.

Organogenesis Holdings (ORGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 3 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.